| Issue Date | Title | Involved Person(s) |
| 2022 | Suizidpräventive Effekte von Ketamin und Esketamin | Plöderl, Martin; Hengartner, Michael P.; Volkmann, Constantin |
| 8-Nov-2021 | Learning about the course of suicidal behavior but not about the effects of SSRIs | Plöderl, Martin; Hengartner, Michael Pascal |
| 2021 | Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression | Hengartner, Michael Pascal; Plöderl, Martin |
| 2021 | Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies | Hengartner, Michael Pascal; Amendola, Simone; Kaminski, Jakob A.; Kindler, Simone; Bschor, Tom, et al |
| 2021 | Latrogenic effects of the FDA black box warning on antidepressants – signal or noise? | Plöderl, Martin; Hengartner, Michael P. |
| 2021 | Maintenance therapy with antidepressants : prophylactic effects or withdrawal reactions? | Plöderl, Martin; Hengartner, Michael P. |
| 2021 | Suicide risk with selective serotonin reuptake inhibitors and other new-generation serotonergic-noradrenergic antidepressants in adults : a meta-analysis of observational studies | Hengartner, Michael P.; Plöderl, Martin; Amendola, Simone; Kindler, Simone; Bschor, Tom, et al |
| 17-Nov-2020 | Moon and suicide : a true effect or a false-positive finding? | Plöderl, Martin; Hengartner, Michael Pascal |
| Jan-2020 | Sertraline in primary care : comments on the PANDA trial | Hengartner, Michael Pascal; Plöderl, Martin; Braillon, Alain; Jakobsen, Janus C.; Gluud, Christian |
| 2020 | Commentary to “antidepressants and suicidality : a re-analysis of the re-analysis” | Plöderl, Martin; Hengartner, Michael Pascal; Bschor, Tom; Kaminski, Jakob André |
